Benefits
Zero-calorie sugar replacement
Steviol glycosides deliver sweetness without contributing to caloric intake or postprandial glucose because the glycosides are not absorbed intact — gut bacteria hydrolyze them to release the steviol aglycone, which is absorbed and excreted as steviol glucuronide in urine. Practical replacement for sucrose in beverages and many foods. Heat-stable, suitable for baking and cooking — though without sugar's volume, browning, and structural properties, requiring bulking agents in baking applications.
Glycemic neutrality
At typical sweetening doses, steviol glycosides do not raise blood glucose or insulin — confirmed in multiple short-term acute and longer-term feeding studies in healthy adults and people with diabetes. Useful in diabetes-friendly diets as a sucrose substitute. Note: this is glycemic neutrality, not active glucose lowering — although some trials in people with type 2 diabetes have shown modest postprandial glucose effects, the mainstream finding is no glycemic impact rather than therapeutic glucose reduction.
Modest blood pressure effects (mixed evidence)
Hsieh et al. 2003 (Clin Ther 25:2797-2808) randomized hypertensive patients to stevioside 1500 mg/day or placebo for 2 years and reported significant BP reduction. However, the result has not been consistently replicated at lower typical-use doses (<500 mg/day stevioside) in subsequent trials. Modest hypotensive effect at high pharmacological doses appears real but is unlikely to be clinically meaningful at typical sweetener intake levels.
Gut microbiome — altered but inconsistent glycemic consequences
Suez/Elinav et al. 2022 (Cell, PMID 35987212) randomized 120 healthy NSS-naive adults to saccharin, sucralose, aspartame, or stevia at sub-ADI doses for 2 weeks. All four NSS distinctly altered stool and oral microbiome and plasma metabolome — including stevia. Saccharin and sucralose significantly impaired glycemic responses; stevia and aspartame did not in this trial. A 2024 systematic review (PMC12020452) found three trials each with stevia, saccharin, and sucralose with no consensus on microbiome impact — methodological heterogeneity (background diet, dose, duration) is the main reason for mixed findings. The honest current picture: stevia plausibly affects the microbiome but the clinical significance for glycemic and metabolic health is unresolved.
WHO 2023 non-sugar sweeteners guideline
WHO's 2023 guideline conditionally recommended against using non-sugar sweeteners for weight control or non-communicable disease risk reduction. The recommendation is based on systematic reviews finding limited long-term weight-control benefit and possible associations (in observational data) with cardiovascular outcomes. Applies to all NSS including stevia. Position has been criticized (Khan et al. 2023, PMC10630128) on grounds that it weighs observational data heavily relative to RCT evidence on substitution effects. The pragmatic interpretation is that substituting stevia for sucrose in already-consumed sweetened products is reasonable; using stevia to add additional sweetened-product consumption is less likely to deliver health benefits.
Dental and cariogenicity profile
Stevia is not metabolized by oral cariogenic bacteria (Streptococcus mutans), making it non-cariogenic — a clear advantage over sucrose for dental health. Some in vitro work suggests modest antibacterial effects on cariogenic species; clinical relevance at sweetener-use levels is small but the absence of caries-promotion is the main benefit.
Forms and regulatory framework
Only purified steviol glycosides (≥95% purity, dominated by Reb A, increasingly Reb M and Reb D) are FDA GRAS for food use. Whole-leaf stevia and crude extracts (10-50% steviol glycosides) are not FDA-approved sweeteners and may legally only be sold as dietary supplements. Newer enzymatically-produced glycosides (Reb M from Pichia pastoris/Komagataella phaffii fermentation) have cleaner taste profiles and are EFSA-approved (EFSA 2019, 2022 specifications amendments). Always check labels — many tabletop products blend stevia with erythritol or other bulking agents.
Mechanism of action
Sweet taste receptor activation
Steviol glycosides bind the T1R2/T1R3 heterodimeric sweet taste receptor on tongue taste buds, generating a sweet sensation 200-400× more potent per molecule than sucrose. Different glycosides bind with slightly different kinetics — explaining the taste differences between stevioside (more licorice-like aftertaste), Reb A (cleaner but with detectable bitterness), and Reb M/Reb D (cleanest, most sucrose-like profile).
Non-absorption of intact glycosides
Steviol glycosides are not absorbed intact in the small intestine. They reach the colon where gut bacteria — primarily Bacteroides species — hydrolyze the glucose units to release steviol (the aglycone). Steviol is absorbed, conjugated to steviol glucuronide in the liver, and excreted predominantly in urine. This explains why steviol glycosides contribute no calories and don't raise blood glucose — the sweet molecule never reaches systemic circulation in its intact form.
Why steviol glycosides interact with the microbiome
Because gut bacteria are required to release steviol from the glycoside, steviol glycoside intake represents a substrate for specific microbial taxa. Repeated exposure can shift microbial composition toward those that metabolize the substrate. This is the mechanistic basis for the microbiome-altering effect documented in Suez 2022 (Cell, PMID 35987212) — a real biological signal, with downstream glycemic significance still being characterized.
Hypotensive mechanism (calcium channel modulation)
Stevioside has been shown in animal and isolated tissue studies to modulate vascular smooth muscle calcium channels and decrease vascular tone — the proposed mechanism for the modest blood pressure reduction observed at high doses. Effect is dose-dependent and unlikely to be clinically meaningful at typical sweetener intakes.
Clinical trials
Multi-arm RCT in 120 healthy NSS-naive adults randomized to 2 weeks of saccharin, sucralose, aspartame, stevia, or control at sub-ADI doses. All four NSS distinctly altered stool and oral microbiome and plasma metabolome. Saccharin and sucralose impaired glycemic responses to oral glucose challenge; stevia and aspartame did not in this trial. Fecal microbiome transplant from human responders to germ-free mice transferred the glycemic phenotype — establishing causation. Important nuance: stevia altered the microbiome without measurable glycemic consequence at the doses and duration studied.
Two-year randomized double-blind placebo-controlled trial in 168 hypertensive Taiwanese adults randomized to stevioside 1500 mg/day or placebo. Significant systolic and diastolic blood pressure reduction in the stevioside arm sustained over 2 years. Notable for trial duration but not consistently replicated at lower typical-use doses; relevance for sweetener-level intake (typically <100 mg/day stevioside equivalent) is limited.
European Food Safety Authority FAF Panel evaluated proposed ADI modification from 4 to 6 or 16 mg/kg body weight/day steviol equivalents. Confirmed the existing ADI of 4 mg/kg/day remains appropriate based on available toxicological evidence. Currently authorized in the EU across 32 food categories. EFSA 2021 (PMC8329987) and 2022 (PMC8826121, PMC9109230) opinions covered the safety of enzymatically-produced rebaudiosides M, D, and AM.
Conditionally recommended against using non-sugar sweeteners for weight control or to reduce risk of NCDs in adults or children. Based on systematic reviews finding limited long-term weight-loss benefit in RCTs and possible associations with type 2 diabetes, cardiovascular disease, and all-cause mortality in observational studies. Applies to stevia along with all other NSS. Khan et al. 2023 (PMC10630128) published a critique arguing the recommendation underweighted RCT substitution-effect evidence relative to observational data.